Elena Pezzolo, Sara Di Leo, Paola Miceli, Alvise Sernicola, Luigi Naldi
{"title":"The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review.","authors":"Elena Pezzolo, Sara Di Leo, Paola Miceli, Alvise Sernicola, Luigi Naldi","doi":"10.4081/dr.2025.10112","DOIUrl":"https://doi.org/10.4081/dr.2025.10112","url":null,"abstract":"<p><p>Mesenchymal stem cell (MSC) therapy holds promise for treating immune-mediated inflammatory skin diseases (IMIDs), particularly when conventional therapies are ineffective. Encouraged by their immunomodulatory capabilities and potential for disease modification, different clinical trials are investigating the efficacy and safety of MSCs in single IMIDs. This review aims to summarize the application of MSCs in IMIDs and explore their future clinical potential. We reviewed published studies from January 2016 to January 2024 on MSC treatment for IMIDs. We retrieved 18 clinical trials and 5 observational studies, encompassing 609 patients with psoriasis, atopic dermatitis (AD), chronic spontaneous urticaria (CSU), alopecia areata (AA), systemic sclerosis (SSc), and systemic lupus erythematosus (SLE). Improvements or complete remission were observed in up to 100% of cases for AA, SSc, and SLE, though complete remission rates were less frequent than improvement rates, ranging from 0% in AD to 50% in CSU. Adverse events (AEs) were generally mild; moderate-to-severe AEs were uncommon (4% in psoriasis, 2.6% in SLE, and 0.7% in SSc), and deaths from all causes were rare (6 patients with SSc and 15 patients with SLE). In conclusion, MSC therapy shows promising results in terms of at least partial clinical improvement for most IMIDs. Its effect is achievable after a single or a few administrations, with no significant toxicity. MSCs may fulfill an unmet need for patients unresponsive to conventional immunomodulating agents. However, most evidence still comes from clinical trials with heterogeneous designs and endpoints. Future larger controlled trials are needed to better elucidate their role in refractory IMIDs.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti
{"title":"Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy.","authors":"Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti","doi":"10.4081/dr.2025.10315","DOIUrl":"https://doi.org/10.4081/dr.2025.10315","url":null,"abstract":"<p><p>Adalimumab (ADA), a monoclonal antibody targeting TNF-α, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz®), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the effectiveness and safety of GP2017 in 171 patients from Emilia-Romagna, Italy. Patients were divided into two groups: 78 transitioned from the ADA originator, and 93 were biologic-naive. Changes in the Psoriasis Area and Severity Index (PASI) were analyzed. In the switch group, PASI scores remained stable, while the naive group achieved significant improvements (PASI 75: 52% at 3 months, 89% at 6 months). Adverse events leading to discontinuation were rare. The findings confirm that GP2017 is as effective and safe as the ADA originator, supporting its use as a cost-effective alternative in the treatment of psoriasis. Biosimilars play a crucial role in promoting equitable access to biologic therapies.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carlotta Bertolina, Marinella Bertolotti, Claudia Leporati, Antonina Maria De Angelis, Sara Delfanti, Luigi Cerbone, Marco Ghiglione, Federica Grosso
{"title":"Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report.","authors":"Carlotta Bertolina, Marinella Bertolotti, Claudia Leporati, Antonina Maria De Angelis, Sara Delfanti, Luigi Cerbone, Marco Ghiglione, Federica Grosso","doi":"10.4081/dr.2025.10324","DOIUrl":"https://doi.org/10.4081/dr.2025.10324","url":null,"abstract":"<p><p>Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response lasting for over 5 years. Significant progress has been achieved in the treatment of advanced melanoma with immune checkpoint inhibitors (ICIs) and targeted therapies using BRAFis and MEKis. While these treatments improve survival, they also pose risks of severe toxicities. Notably, when targeted therapy follows immunotherapy, immune-mediated toxicities may emerge months later due to tumor microenvironment modulation. Despite these risks, both approaches offer a durable response in eligible patients. Further understanding is needed to determine how prior immunotherapy may influence subsequent toxicity risks of target therapy. Understanding these factors could optimize treatment strategies and improve patient outcomes.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Caterina Mariarosaria Giorgio, Gaetano Licata, Maria Maddalena Nicoletti, Eugenia Veronica Di Brizzi, Vittorio Tancredi, Giuseppe Argenziano, Valentina Cozza, Adone Baroni
{"title":"Post-COVID-19 resurgence of scabies in Campania, Italy: the hidden burden and challenges in surveillance.","authors":"Caterina Mariarosaria Giorgio, Gaetano Licata, Maria Maddalena Nicoletti, Eugenia Veronica Di Brizzi, Vittorio Tancredi, Giuseppe Argenziano, Valentina Cozza, Adone Baroni","doi":"10.4081/dr.2025.10409","DOIUrl":"https://doi.org/10.4081/dr.2025.10409","url":null,"abstract":"<p><p>Scabies, a contagious parasitic skin disease caused by Sarcoptes scabiei, has shown a marked resurgence in several European regions following the COVID-19 pandemic. In Campania, Italy, reported cases increased from 42 in 2020 to 748 in 2024, according to the regional surveillance system (Sistema Premal-UOD). However, the true burden of disease is likely underestimated due to widespread underreporting, delayed diagnosis, and a hidden reservoir of undetected or self-treated cases. This study analyzes epidemiological trends in Campania, highlights limitations in surveillance, and examines the role of pseudo-resistance in treatment failures. The findings underscore the need for robust monitoring, accurate diagnostics, and public health interventions to reduce the ongoing spread of scabies in the region.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katarzyna Korecka, Monika Bowszyc-Dmochowska, Nina Łabędź, Ryszard Żaba, Aleksandra Dańczak-Pazdrowska, Adriana Polańska
{"title":"Keratosis lichenoides chronica: a case report with dermatoscopic and ultrasonographic analysis.","authors":"Katarzyna Korecka, Monika Bowszyc-Dmochowska, Nina Łabędź, Ryszard Żaba, Aleksandra Dańczak-Pazdrowska, Adriana Polańska","doi":"10.4081/dr.2025.10093","DOIUrl":"https://doi.org/10.4081/dr.2025.10093","url":null,"abstract":"<p><p>We present the case of a 46-year-old woman with a long-standing history of linear erythematosquamous papules on the arms and thighs, which were unresponsive to treatment with topical corticosteroids. She also reported lesions typical of seborrheic dermatitis located on her face. After performing a clinical examination, dermatoscopy, high-frequency ultrasonography (HFUS), and a biopsy for histopathological examination, a diagnosis of keratosis lichenoides chronica (KLC) was obtained. Also known as Nekam disease, keratosis lichenoides chronica is a rare, chronic inflammatory skin disease characterized by diffuse, linearly arranged erythro- or erythematosquamous papules with a thin, keratotic plug.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anamnestic, clinical, and dermoscopic predictors of malignancy in melanocytic lesions with peripheral globules: a retrospective study.","authors":"Enrico Zelin, Vanessa Mazzoletti, Jessica Paladin, Andrea Corio, Raffaele Dante Caposiena Caro, Giulia Bazzacco, Enzo Errichetti, Nicola Di Meo, Iris Zalaudek","doi":"10.4081/dr.2025.10334","DOIUrl":"https://doi.org/10.4081/dr.2025.10334","url":null,"abstract":"<p><p>Melanocytic lesions with peripheral globules (MLPGs) usually represent lesions in an active growth phase and should be carefully evaluated in adults and the elderly, since melanoma can rarely present with this pattern. The primary aim of this study was to identify anamnestic, clinical, and dermoscopic features associated with malignancy (histologic outcome of melanoma) in MLPGs. The secondary aim was to describe the frequency of these features. We conducted a retrospective cross-sectional observational study, evaluating anamnestic, clinical, and dermoscopic features of MLPGs excised at the Dermatology Clinic of Trieste, Italy (January 2019-June 2023). The association between each variable and the histologic outcome (nevus or melanoma) was assessed using Fisher's exact test. Differences in age and lesion diameter distribution between nevi and melanomas were analyzed using Student's t-test for independent variables. Several lesion characteristics were associated with malignancy, including a personal history of melanoma (p=0.0069), localization on the lower limbs (p=0.0215), and lesion diameter ≥6 mm (p=0.0025). Several dermoscopic features were also associated with malignancy, namely non-circumferential peripheral globules (p=0.0406), regression (p=0.0042), evident vascular pattern/pink areas (p=0.0007), inverse network (p=0.0243), and asymmetric central globules (p=0.0057). Additionally, the comparison between melanoma and nevi groups confirmed that malignant lesions were characterized by a higher mean age at diagnosis (p=0.0237) and a larger mean diameter (p=0.000112). This study provides practical guidance for the management of MLPGs, highlighting that several anamnestic, clinical, and dermoscopic features are suggestive of malignancy.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicolò Rivetti, Camilla Vassallo, Stefania Barruscotti, Valeria Brazzelli, Carlo Francesco Tomasini
{"title":"Linear psoriasis or ILVEN? A pediatric case unraveling the mosaic puzzle.","authors":"Nicolò Rivetti, Camilla Vassallo, Stefania Barruscotti, Valeria Brazzelli, Carlo Francesco Tomasini","doi":"10.4081/dr.2025.10429","DOIUrl":"https://doi.org/10.4081/dr.2025.10429","url":null,"abstract":"<p><p>Linear psoriasiform eruptions in children are diagnostically challenging, particularly when they follow Blaschko's lines. The main differential diagnosis includes inflammatory linear verrucous epidermal nevus (ILVEN) and linear psoriasis (LP), a rare mosaic variant. We describe the case of a 5-year-old boy with extensive unilateral lesions clinically suggestive of both entities. Histology revealed Munro microabscesses and psoriasiform hyperplasia. The patient showed rapid improvement with topical calcipotriol/betamethasone, followed by long-term remission. Notably, after 8 years of follow-up, the lesions remained strictly confined to the original Blaschkoid distribution, with no extracutaneous involvement and only mild recurrences. This clinical course strongly supports the diagnosis of isolated linear psoriasis (type 1 mosaicism). Few pediatric cases in the literature have documented such a long and stable evolution, making this report a valuable contribution to the distinction between LP and ILVEN. The case highlights the importance of integrating clinical, histological, and longitudinal data when evaluating linear dermatoses in children.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo
{"title":"Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab.","authors":"Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo","doi":"10.4081/dr.2025.10414","DOIUrl":"https://doi.org/10.4081/dr.2025.10414","url":null,"abstract":"<p><p>Paradoxical psoriasis is a rare but increasingly recognized adverse effect of anti-TNF-α therapy, characterized by the onset or exacerbation of psoriatic lesions in patients treated for other immune-mediated conditions. We report the case of a 47-year-old woman with chronic plaque psoriasis who developed severe generalized pustular psoriasis (GPP) after six months of treatment with an adalimumab biosimilar. Given the extent and severity of the eruption and following inadequate response to previous conventional therapies, the patient was treated with brodalumab, an IL-17RA inhibitor. Rapid and complete remission of both pustular and plaque psoriasis was achieved and maintained for over 60 weeks. This case supports the efficacy of IL-17 pathway blockade in managing paradoxical GPP and highlights the importance of prompt recognition and appropriate therapeutic switching in severe biologic-induced psoriasis.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Khalid Alwunais, Jamal Alqahtani, Abdullah Ali N Aljalfan, Hadeel Alotaibi
{"title":"Autosomal recessive woolly hair/hypotrichosis with homozygous mutation in the <i>LIPH</i> gene: a case report.","authors":"Khalid Alwunais, Jamal Alqahtani, Abdullah Ali N Aljalfan, Hadeel Alotaibi","doi":"10.4081/dr.2025.10177","DOIUrl":"https://doi.org/10.4081/dr.2025.10177","url":null,"abstract":"<p><p>Autosomal recessive woolly hair/hypotrichosis (ARWH/H) is a hereditary hair disorder characterized by sparse, short, and curly hair. Mutations in the Lipase H (LIPH) gene, LPAR6, or other genes cause this hereditary hair condition. We report a case of an 11-month-old Saudi boy who presented to our dermatology clinic at King Fahad University Hospital in Al-Khobar (Saudi Arabia) with short, non-growing hair since birth. DNA sequencing revealed a homozygous mutation in the LIPH gene at c.280_369dup. Our patient was diagnosed with ARWH/H resulting from a homozygous mutation in LIPH.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Trang Thi Thuy Vu, Chuyen Thi Hong Nguyen, Trung The Van
{"title":"S-MAPA: bridging the gap in psoriasis severity assessment.","authors":"Trang Thi Thuy Vu, Chuyen Thi Hong Nguyen, Trung The Van","doi":"10.4081/dr.2025.10231","DOIUrl":"https://doi.org/10.4081/dr.2025.10231","url":null,"abstract":"<p><p>The Psoriasis Area and Severity Index (PASI) is widely used to evaluate psoriatic disease activity in clinical settings; however, its limitations hinder its practicality in routine use. The Simple-Measure for Assessing Psoriasis Severity (S-MAPA) has emerged as a promising tool addressing these limitations, providing a more feasible approach for assessing disease severity. This study aimed to evaluate the S-MAPA as a sensitive and practical alternative to existing instruments for measuring psoriasis severity. Patients with psoriasis were assessed using body surface area (BSA), the Physician's Global Assessment (PGA), S-MAPA, PASI, and Dermatology Life Quality Index (DLQI). Plasma high-sensitivity C-reactive protein (hs-CRP) levels were also measured. Spearman's correlation analysis compared the relationships between these assessment tools and hs-CRP levels. In total, 100 assessments were conducted between January and July 2019. The S-MAPA score and PASI showed a strong positive correlation with disease severity (r=0.9315, p<0.01). Both the S-MAPA score and PASI exhibited comparable correlations with hs-CRP levels (r=0.5299 vs. 0.5316) and the DLQI (r=0.2533 vs. 0.2641). The S-MAPA score demonstrated stronger correlations with the PASI, DLQI, and hs-CRP level than with BSA or the PGA score. The area under the receiver operating characteristic curve for the S-MAPA was 0.9787, with an optimal cut-off value of 138 for predicting severe psoriasis (sensitivity, 92.59%; specificity, 95.89%). Based on our findings, the S-MAPA is a reliable and practical alternative for assessing the severity of psoriasis in clinical practice, offering advantages over conventional measures.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}